Mark Hellner

Array ( [id] => 19134006 [patent_doc_number] => RE049949 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2024-04-30 [patent_title] => Reducing risk of contracting clostridium-difficile associated disease [patent_app_type] => reissue [patent_app_number] => 16/738434 [patent_app_country] => US [patent_app_date] => 2020-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 22 [patent_no_of_words] => 16117 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16738434 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17376351 [patent_doc_number] => RE048908 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2022-02-01 [patent_title] => DNA vector production system [patent_app_type] => reissue [patent_app_number] => 16/668950 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 9 [patent_no_of_words] => 13144 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16668950 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17376352 [patent_doc_number] => RE048909 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2022-02-01 [patent_title] => Tagged oligonucleotides and their use in nucleic acid amplification methods [patent_app_type] => reissue [patent_app_number] => 16/398161 [patent_app_country] => US [patent_app_date] => 2019-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 22 [patent_no_of_words] => 37886 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 329 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16398161 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17305667 [patent_doc_number] => RE048863 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2021-12-28 [patent_title] => Compositions relating to a mutant [patent_app_type] => reissue [patent_app_number] => 16/388011 [patent_app_country] => US [patent_app_date] => 2019-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 56 [patent_no_of_words] => 62110 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16388011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17305666 [patent_doc_number] => RE048862 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2021-12-28 [patent_title] => Compositions relating to a mutant [patent_app_type] => reissue [patent_app_number] => 16/387999 [patent_app_country] => US [patent_app_date] => 2019-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 56 [patent_no_of_words] => 61694 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16387999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17087948 [patent_doc_number] => RE048731 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2021-09-14 [patent_title] => Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases [patent_app_type] => reissue [patent_app_number] => 16/387315 [patent_app_country] => US [patent_app_date] => 2019-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49778 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16387315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16968694 [patent_doc_number] => RE048651 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2021-07-20 [patent_title] => Production cell line enhancers [patent_app_type] => reissue [patent_app_number] => 16/387134 [patent_app_country] => US [patent_app_date] => 2019-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 11034 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16387134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17176762 [patent_doc_number] => RE048787 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2021-10-26 [patent_title] => Humanised antibodies [patent_app_type] => reissue [patent_app_number] => 16/378731 [patent_app_country] => US [patent_app_date] => 2019-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 19 [patent_no_of_words] => 15619 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16378731 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16907541 [patent_doc_number] => RE048599 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2021-06-22 [patent_title] => Compositions comprising TLIA-Ig fusion protein for the regulation of T regulatory cells, and methods for their use [patent_app_type] => reissue [patent_app_number] => 16/366676 [patent_app_country] => US [patent_app_date] => 2019-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 36 [patent_no_of_words] => 30682 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16366676 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16784362 [patent_doc_number] => RE048536 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2021-04-27 [patent_title] => Collagen sponge [patent_app_type] => reissue [patent_app_number] => 16/364805 [patent_app_country] => US [patent_app_date] => 2019-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 7122 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16364805 [rel_patent_id] =>[rel_patent_doc_number] =>)